Revolution Medicines (RVMD) Liabilities and Shareholders Equity (2019 - 2026)

Revolution Medicines has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 4.72% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $9.3 billion (up 9.35% YoY), and the FY2025 full-year result was $2.4 billion, down 7.97% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $2.3 billion, down from $2.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $2.6 billion in Q4 2024, with the low at $632.8 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.8 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity decreased 18.25% in 2022 and surged 153.93% in 2023.
• Tracing RVMD's Liabilities and Shareholders Equity over 5 years: stood at $811.9 million in 2022, then surged by 153.93% to $2.1 billion in 2023, then grew by 24.09% to $2.6 billion in 2024, then slipped by 7.97% to $2.4 billion in 2025, then declined by 4.28% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.

Peer Comparison